Zuberitamab, Anruixi® is a Class I innovative monoclonal antibody developed by BioRay Pharmaceutical. This drug targets CD20-positive B-cells and has been specifically approved for treating CD20-positive diffuse large B-cell lymphoma (DLBCL). It marks a significant milestone as China's first domestically developed anti-CD20 antibody to be approved for commercial use.

In clinical studies, Zuberitamab demonstrated superior efficacy compared to other treatments like Rituximab. It was shown to induce better overall response rates and complete response rates when combined with chemotherapy (CHOP regimen) in patients with early-stage DLBCL. Notably, it also showed improved long-term survival benefits, such as better progression-free survival (PFS) and overall survival (OS) rates?

tamab operates by triggering immune responses such as antibody-dependent cell-mediated cytotoxicity (ADCC), which leads to the destruction of B-cells. It has demonstrated a stronger ADCC effect than other available treatments

ug is not only indicated for lymphoma but is also being investigated for use in autoimmune diseases like primary immune thrombocytopenia

BioRay’s sixth marketed product and represents a major development in immunotherapy, positioning the company as a key player in the biopharmaceutical market in China